Silicosis: A Patient Guide
At a Glance
Silicosis is permanent lung scarring caused by breathing crystalline silica dust. There is no cure to reverse the scars, so stopping exposure and receiving long-term monitoring and supportive care are essential to limit progression and protect quality of life.
Silicosis is a chronic and irreversible lung disease caused by the inhalation of tiny particles of crystalline silica, a mineral naturally found in stone, sand, and clay. While it is one of the oldest known occupational diseases, it has seen a modern resurgence in industries like engineered stone countertop fabrication. Workers in these industries may be exposed to much higher concentrations of silica than in traditional mining or construction [1][2]. When these microscopic dust particles are breathed in, they travel deep into the lungs and become trapped in the air sacs, where they trigger an immune response [3][4].
The biological damage occurs because the lungs’ primary defense cells, called macrophages, attempt to swallow and break down the silica particles. Unlike bacteria or organic dust, silica is a hard mineral that the cells cannot destroy; instead, the particles damage the cells from the inside, causing them to die and release inflammatory signals [3][5]. This process creates a continuous cycle of inflammation and tissue repair that leads to the formation of fibrosis, or scar tissue [6][7]. Over time, these scars can grow into small nodules or large masses that replace healthy lung tissue, making it increasingly difficult for the lungs to transfer oxygen into the bloodstream [8][9].
The way silicosis behaves depends heavily on the intensity and duration of the dust exposure. Chronic silicosis is the most common form, typically developing after approximately ten or more years of lower-level exposure, and it may cause few symptoms in its early stages [10][8]. In contrast, accelerated silicosis can appear sooner (often in two to ten years) following high-intensity exposure and frequently progresses much more rapidly [11][2]. The rarest and most severe presentation, acute silicoproteinosis, can develop within weeks or months of massive exposure, quickly leading to significant respiratory failure [12][13].
Because there is currently no medical cure to reverse the scarring, the standard of care centers on avoiding further exposure as completely as possible and managing the symptoms. Even after a person leaves a high-dust environment, the particles already in the lungs can continue to cause damage, making long-term, individualized monitoring essential. This tracking looks for progression into progressive massive fibrosis or the development of secondary complications like Tuberculosis (TB) [14][15]. Management focuses on supportive care—such as treating coexisting airway blockages with inhalers, updating vaccinations to prevent infections, and participating in pulmonary rehabilitation—to help patients maintain their quality of life, manage their symptoms, and navigate the long-term realities of the condition [16][17]. Occupational, financial, and vocational support are also crucial parts of navigating a silicosis diagnosis.
In this guide
6 chapters
Understanding Silicosis: Biology and Subtypes
Learn how silica dust causes lung scarring, who is at risk, and how acute, accelerated, chronic, simple, and complicated silicosis differ, including PMF.
Symptoms and When to Seek Urgent Care
Learn how silicosis symptoms can change over time, which warning signs require emergency care, and when to contact your doctor about breathing problems.
Getting an Accurate Diagnosis: Imaging and Lung Function
Learn how silicosis is diagnosed using work history, chest X-ray, HRCT, ILO scoring, lung function tests, DLCO, and when a biopsy may be needed in some cases.
Standard of Care and Treatment Realities
Learn how silicosis is managed when lung scarring cannot be reversed, including exposure control, oxygen, rehabilitation, complications, and transplant evaluation.
Complications and Related Conditions
Learn about silicosis complications, including TB, lung cancer, autoimmune disease, COPD, pulmonary hypertension, heart failure, and warning signs to report.
Long-Term Monitoring and Living with Silicosis
Learn how to live with silicosis through long-term monitoring, lung tests, TB screening, vaccines, smoking cessation, and support for work-related changes.
Common questions in this guide
What leads to silicosis?
How do chronic, accelerated, and acute silicosis differ?
Can lung damage from silicosis be reversed?
How is silicosis monitored over time?
What care can help manage silicosis after silica exposure stops?
Get notified when new evidence is published on Silicosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
Characterisation of dust emissions from machined engineered stones to understand the hazard for accelerated silicosis.
Ramkissoon C, Gaskin S, Thredgold L, et al.
Scientific reports 2022; (12(1)):4351 doi:10.1038/s41598-022-08378-8.
PMID: 35288630 - 2
A review of silicosis and other silica-related diseases in the engineered stone countertop processing industry.
Fazio JC, Viragh K, Houlroyd J, Gandhi SA
Journal of occupational medicine and toxicology (London, England) 2025; (20(1)):9 doi:10.1186/s12995-025-00455-8.
PMID: 40098042 - 3
RAB20 deficiency promotes the development of silicosis via NLRP3 inflammasome.
Peng Z, Duan M, Zhao K, et al.
Frontiers in immunology 2022; (13()):967299 doi:10.3389/fimmu.2022.967299.
PMID: 36131930 - 4
Impaired interferon-γ signaling promotes the development of silicosis.
Peng Z, Duan M, Tang Y, et al.
iScience 2022; (25(7)):104647 doi:10.1016/j.isci.2022.104647.
PMID: 35800765 - 5
Role of metabolic reprogramming in pro-inflammatory cytokine secretion from LPS or silica-activated macrophages.
Marrocco A, Ortiz LA
Frontiers in immunology 2022; (13()):936167 doi:10.3389/fimmu.2022.936167.
PMID: 36341426 - 6
Linking NLRP3 inflammasome and pulmonary fibrosis: mechanistic insights and promising therapeutic avenues.
Gairola S, Sinha A, Kaundal RK
Inflammopharmacology 2024; (32(1)):287-305 doi:10.1007/s10787-023-01389-5.
PMID: 37991660 - 7
Astragaloside IV alleviates silica‑induced pulmonary fibrosis via inactivation of the TGF‑β1/Smad2/3 signaling pathway.
Li N, Wu K, Feng F, et al.
International journal of molecular medicine 2021; (47(3)).
PMID: 33448318 - 8
Silicosis Epidemic among Engineered Stone Countertop Workers: Pictorial Review.
Lateef S, Oh A, Chung JH, et al.
Radiographics : a review publication of the Radiological Society of North America, Inc 2026; (46(3)):e250079 doi:10.1148/rg.250079.
PMID: 41712445 - 9
Silica, Silicosis, and Autoimmunity.
Pollard KM
Frontiers in immunology 2016; (7()):97 doi:10.3389/fimmu.2016.00097.
PMID: 27014276 - 10
Notes from the Field: Update: Silicosis Mortality - United States, 1999-2013.
Mazurek JM, Schleiff PL, Wood JM, et al.
MMWR. Morbidity and mortality weekly report 2015; (64(23)):653-4.
PMID: 26086638 - 11
Silicosis: No longer exclusively a chronic disease.
Cena AC, Cena LG
JAAPA : official journal of the American Academy of Physician Assistants 2024; (37(9)):14-20 doi:10.1097/01.JAA.0000000000000103.
PMID: 39162647 - 12
Artificial stone-associated silicosis with concurrent Cryptococcus infection.
Shen HS, Lai YT, Tsai HC, Chang SC
Respirology case reports 2021; (9(6)):e00765 doi:10.1002/rcr2.765.
PMID: 33976894 - 13
Artificial stone-associated silicosis: clinical-pathological-radiological correlates of disease.
Levin K, McLean C, Hoy R
Respirology case reports 2019; (7(7)):e00470 doi:10.1002/rcr2.470.
PMID: 31428428 - 14
Artificial Stone Silicosis: Rapid Progression Following Exposure Cessation.
León-Jiménez A, Hidalgo-Molina A, Conde-Sánchez MÁ, et al.
Chest 2020; (158(3)):1060-1068 doi:10.1016/j.chest.2020.03.026.
PMID: 32563682 - 15
The association between silica exposure, silicosis and tuberculosis: a systematic review and meta-analysis.
Ehrlich R, Akugizibwe P, Siegfried N, Rees D
BMC public health 2021; (21(1)):953 doi:10.1186/s12889-021-10711-1.
PMID: 34016067 - 16
Silicosis: from pathogenesis to therapeutics.
Yang B, Liu X, Peng C, et al.
Frontiers in pharmacology 2025; (16()):1516200 doi:10.3389/fphar.2025.1516200.
PMID: 39944632 - 17
Silica-associated lung disease: An old-world exposure in modern industries.
Barnes H, Goh NSL, Leong TL, Hoy R
Respirology (Carlton, Vic.) 2019; (24(12)):1165-1175 doi:10.1111/resp.13695.
PMID: 31517432
This page is for informational purposes only and does not constitute medical advice. A pulmonologist or occupational-health clinician can interpret your exposure history and imaging and guide monitoring.